825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Vaxcyte Enters $500 Million Sales Agreement with Leerink Partners
Vaxcyte Enters Underwriting Agreement for $550 Million Stock Offering
Vaxcyte, Inc. Amends Executive Change in Control Agreements
Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
Material Contracts
Vaxcyte Q2 2025 Financial Results and VAX-31 Vaccine Update
Shareholder votes
FY 2024
Q3
Q2
Q1
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence